Complete Genome Sequence of Bacillus toyonensis Strain HA0190, Isolated from a Commercial Hydroxyapatite Product Extensively Used as a Synthetic Bone Graft Substitute

Sung Guk Kim; Miseon Park; Christine V Summage-West; Seonggi Min; Steven L Foley

doi:10.1128/mra.00105-22

Complete Genome Sequence of Bacillus toyonensis Strain HA0190, Isolated from a Commercial Hydroxyapatite Product Extensively Used as a Synthetic Bone Graft Substitute

Microbiol Resour Announc. 2022 Apr 21;11(4):e0010522. doi: 10.1128/mra.00105-22. Epub 2022 Apr 4.

Authors

Sung Guk Kim¹, Miseon Park², Christine V Summage-West¹, Seonggi Min², Steven L Foley³

Affiliations

¹ Surveillance/Diagnostic Laboratory, Office of Scientific Coordination, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, Arkansas, USA.
² Division of Biochemical Toxicology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, Arkansas, USA.
³ Division of Microbiology, National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, Arkansas, USA.

Abstract

Bacillus toyonensis is a member of the Bacillus cereus group and is used as a probiotic in animal feeds and biological applications. We report the 5.8-Mbp genome sequence of strain HA0190, an isolate from a commercial hydroxyapatite nanoparticle product. The genome contains a circular chromosome and two plasmids, pBT001 and pBT002.

Grants and funding

HHS | U.S. Food and Drug Administration (FDA)